<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Meclizine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Meclizine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Meclizine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Meclizine 25mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Motion sickness prevention</strong>
            <ul>
              <li>25–50 mg PO 1 hour before travel, may repeat every 24 hours as needed</li>
            </ul>
          </li>
          <li><strong>Vertigo associated with vestibular system disorders</strong>
            <ul>
              <li>25–100 mg PO daily in divided doses (e.g., 25 mg every 12–24 hours or 50 mg daily)</li>
              <li>Titrate to lowest effective dose</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness</li>
          <li>Management of vertigo associated with diseases affecting the vestibular system (e.g., labyrinthitis, Meniere's disease)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to meclizine</li>
          <li>Sedation and drowsiness common: caution with watchkeeping, machinery operation, and alcohol/CNS depressants</li>
          <li>Anticholinergic effects: caution in narrow-angle glaucoma, urinary retention, prostatic hypertrophy</li>
          <li>Older adults: increased risk of anticholinergic effects (confusion, falls, dry mouth, constipation)</li>
          <li>Avoid in pregnancy unless clearly needed (Category B; some sources recommend avoiding first trimester)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Drowsiness, sedation, fatigue</li>
          <li>Dry mouth, blurred vision</li>
          <li>Urinary retention (especially in susceptible patients)</li>
          <li>Headache, dizziness (paradoxical)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>For motion sickness: take 1 hour before travel for best effect</li>
          <li>Avoid alcohol and other CNS depressants</li>
          <li>Chewable tablets may be chewed or swallowed whole</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom relief (nausea, vertigo)</li>
          <li>Sedation/functional impairment (especially with first dose and during critical duties)</li>
          <li>Anticholinergic side effects (dry mouth, urinary retention, confusion in older adults)</li>
          <li>If vertigo persists or worsens: reassess for alternate diagnosis or need for medical evaluation</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Operational safety: warn about drowsiness; first dose should be given when not on critical watch duties</li>
          <li>Motion sickness: timing is important—dose 1 hour before departure when possible</li>
          <li>If symptoms don't improve within 24–48 hours, consider alternate diagnosis (e.g., central vertigo, posterior circulation stroke in older/high-risk patients)</li>
          <li>Document response to guide future selection; some patients respond better to alternate agents (dimenhydrinate, scopolamine)</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (Bonamine - meclizine): <a href="https://pdf.hres.ca/dpd_pm/00067339.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067339.PDF</a></li>
          <li>Medscape drug reference (meclizine): <a href="https://reference.medscape.com/drug/antivert-bonine-meclizine-342476" target="_blank" rel="noopener">https://reference.medscape.com/drug/antivert-bonine-meclizine-342476</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
